If you need to value a company in India — for a funding round, an ESOP grant, a merger, or a regulatory filing — the Comparable Company Multiple (CCM) method is almost certainly the first method your valuer, banker, or investor will reach for. It is the most widely applied Valuation technique in Indian M&A, private equity, and investment due diligence. Its logic is simple: if you want to know what a business is worth, look at what the market is currently paying for similar businesses.
Yet simplicity of concept belies significant complexity of execution. Selecting the right comparable companies, computing and adjusting multiples correctly, applying the appropriate discounts for unlisted status, and bridging from Enterprise Value to per-share Equity Value — each of these steps requires professional judgement grounded in sector knowledge and financial rigour. Errors at any stage produce a Valuation that misleads rather than informs, with real financial and legal consequences. This guide deconstructs the CCM method step-by-step — from first principles through to a complete, worked numerical example using an Indian company — so that investors, CFOs, and finance professionals can understand precisely how a defensible CCM Valuation is constructed.
The Market Approach — of which CCM is the primary technique — is one of three accepted Valuation approaches alongside the Income Approach (DCF) and the Asset Approach (Net Asset Value). Our team at Elite Valuation applies the CCM method on assignments spanning unlisted company share Valuation, ESOP grant-date fair value, preferential allotment pricing, FEMA compliance, and M&A transaction support across all major Indian sectors.
Key Takeaways
- CCM is a relative Valuation method — it anchors value to observable market prices of comparable listed companies, not to internal projections like DCF.
- The six-step CCM process — define the universe → screen comparables → extract multiples → normalise → apply to subject → bridge to equity — must be followed in sequence with documented rationale at each stage.
- EV/EBITDA is the primary multiple for most Indian M&A and investment Valuation; EV/Revenue is used for early-stage or loss-making companies; P/E for financial services and mature businesses.
- Median, not mean, is used for the central multiple — outliers in a small comparable set distort the mean significantly, whereas the median is robust.
- Unlisted company CCM requires a Discount for Lack of Marketability (DLOM) of 15–35% to adjust listed-market multiples for illiquidity — this is a mandatory professional judgement step.
- DLOC (Discount for Lack of Control) is not applicable for listed subject companies — CCM multiples derived from traded prices already reflect a minority, marketable interest. Applying DLOC on top is a double discount. DLOC applies only when valuing a minority stake in an unlisted company after the EV-to-equity bridge.
- The EV-to-Equity bridge — subtracting net debt, minority interest, and debt-like items from Enterprise Value — is where most CCM errors occur; each line item must be individually verified.
- An IBBI-registered valuer is mandated for all regulatory CCM Valuation assignments in India and brings documented, professionally accountable methodology to the exercise.
🎁 Get the Free CCM Valuation Excel Template
Download our comparable company analysis template — used by our team on real client Valuations. Free, no macros, ready to use.
What Is the Comparable Company Multiple Method?
The Comparable Company Multiple method is a relative Valuation technique that determines the fair value of a subject company by referencing the trading multiples of comparable publicly listed companies. The underlying principle is the Law of One Price — in an efficient market, two businesses with identical economic characteristics should trade at the same multiple of their underlying financial metrics. By identifying companies whose economics are similar to the subject company and observing what the market pays for them, the valuer arrives at a market-validated Valuation benchmark.
CCM is classified under the Market Approach to Valuation — one of three primary approaches recognised by the International Valuation Standards (IVS), adopted by the IBBI Valuation Standards framework governing all IBBI-registered valuer assignments in India. Unlike the Income Approach (which values a business based on its own future cash flow projections) or the Asset Approach (which values the net realisable assets), the Market Approach grounds value in observable, current market transaction data — making it empirically anchored and more difficult to manipulate through assumption engineering.
SNIPPET — Definition: Comparable Company Multiple Method
The Comparable Company Multiple (CCM) method is a relative Valuation approach that determines a company's fair value by multiplying its financial metrics (EBITDA, Revenue, EBIT, PAT) by the corresponding median trading multiples of comparable listed peer companies. The resulting Enterprise Value is then bridged to Equity Value by adjusting for net debt, minority interest, and other balance sheet items. At Elite Valuation, our team applies the CCM method across M&A, ESOP, FEMA, SEBI, and Companies Act Valuation assignments in India.
Where Does CCM Fit in Indian Valuation Practice?
CCM is best suited for companies that have identifiable listed peers, positive and meaningful EBITDA, and operate in sectors where market data is available on the NSE or BSE. It is the dominant method in Indian M&A transaction Valuation, private equity investment pricing, and regulatory Valuation exercises. Where the DCF method is better suited for modelling long-run intrinsic value — particularly for companies with distinctive growth trajectories — CCM provides the market-reality check that anchors the Valuation to current investor sentiment and sector pricing.
📊 The Three Valuation Approaches — How CCM Fits
| Attribute | CCM (Market Approach) | DCF (Income Approach) |
|---|---|---|
| Data Source | Observable listed market prices | Internal financial projections |
| Time Horizon | Current / trailing / forward 12 months | 5–7 year explicit projection period |
| Manipulation Risk | Lower — anchored to market data | Higher — assumption-sensitive |
| Best Suited For | Companies with clear listed peers, positive EBITDA | Companies with predictable cash flows, stable growth |
| Speed | Fast once comps identified | Time-intensive — requires detailed model |
How Do You Identify the Right Peer Companies?
The quality of a CCM Valuation is entirely dependent on the quality of the comparable company set. A poorly assembled peer group — companies that are superficially similar but economically different — produces multiples that lead the Valuation astray. This is the most judgement-intensive step in the CCM process, and it is where IBBI-registered valuers bring irreplaceable professional expertise.
The screening process applies five criteria in sequence, eliminating companies that do not meet the threshold at each stage until a final comparable set of five to eight companies is established.
1. Industry and Sector Classification
Begin with the same NIC (National Industrial Classification) code or GICS sector. For an unlisted B2B healthcare technology company, you start with NSE/BSE-listed healthcare IT and health management system companies. This initial screen typically yields 15–25 candidates in most Indian sectors.
2. Business Model Alignment
Within the sector, filter for companies with a similar business model — same revenue type (software licence vs SaaS subscription vs services), same customer segment (B2B hospital chains vs B2C consumer health), and similar value chain position. A hospital chain is not a comparable for a health software company, even though both are in "healthcare."
3. Size Comparability
Filter for companies within a size band relative to the subject company. The commonly applied range is 0.5x to 3.0x of the subject's revenue. A Rs. 85 crore revenue subject company would look at peers with revenue between Rs. 42 crore and Rs. 250 crore. Very large caps (Rs. 5,000+ crore revenue) may command structural market liquidity premiums that distort the multiple.
4. Financial Health Filter
Exclude companies with negative EBITDA (cannot compute EV/EBITDA meaningfully), companies under insolvency proceedings, companies with pending regulatory enforcement actions that distort market prices, and companies that have not filed audited financials for the last three years.
5. Growth and Margin Proximity
Assess whether the shortlisted companies have a broadly comparable growth trajectory (revenue CAGR within a 2x range of the subject's) and EBITDA margin profile. A company with 35% EBITDA margins will command structurally higher multiples than a 12% margin peer — including them in the same comparable set without adjustment produces a misleading median multiple.
6. Cross-Border Peers (if needed)
When the Indian listed universe yields fewer than three pure-play peers, international listed comparables from the US, Singapore, or UK may be included. Their multiples are adjusted for India's country risk premium — typically by applying a discount of 15–25% to reflect differences in market depth, liquidity, and risk environment.
■■ Peer Selection Caution: The most common CCM error is including comparables that are too large or too diversified relative to the subject company. A conglomerate with a healthcare IT division is not a comparable for a pure-play healthcare IT company — the conglomerate's multiple reflects its blended business mix, not the economics of its healthcare segment. Our team documents the inclusion and exclusion rationale for every candidate company considered in the screening process.
Which Valuation Multiples Drive the CCM Engine?
Not all multiples are equally appropriate for all companies or sectors. The choice of multiple — and the metric it is applied to — must reflect the financial characteristics of the subject company and what investors in that sector actually focus on when pricing businesses. Using the wrong multiple is as harmful as using the wrong comparable company.
EV / EBITDA — Primary Multiple for Most Sectors
Most Widely Used
Capital-Structure Neutral
- What it measures: Enterprise Value relative to operating earnings before interest, tax, depreciation, and amortisation. It isolates operational performance from financing choices (capital structure) and accounting policy choices (depreciation method). Formula: EV ÷ EBITDA.
- Best for: Manufacturing, Technology Services, Consumer, Pharma, Healthcare — any profitable company with meaningful operating assets. EV/EBITDA is the standard multiple used in most Indian M&A Valuation reports and is explicitly referenced in SEBI transaction documents.
- Limitation: Ignores differences in capital expenditure requirements — two companies with the same EBITDA but different maintenance capex have different free cash flow profiles. Where capex intensity varies significantly between peers, EV/EBIT or EV/FCF may supplement EV/EBITDA.
EV / Revenue — For Growth or Loss-Making Companies
Growth Companies
Use with Caution
- What it measures: Enterprise Value relative to total revenue. Formula: EV ÷ Revenue.
- Best for: SaaS companies, early-stage technology businesses, and companies where EBITDA is temporarily negative (pre-profitability stage) or distorted by heavy investment spending. Also used as a secondary multiple for cross-validation when EV/EBITDA is the primary.
- Limitation: Revenue-based multiples completely ignore profitability — a high EV/Revenue multiple applied to a low-margin business can produce a gross overvaluation. Always cross-check EV/Revenue-derived valuations against an EBITDA-margin-adjusted framework.
P / E Ratio — For Mature and Financial Services Companies
Financial Services
Mature Businesses
- What it measures: Market Price per share relative to Earnings per share (PAT basis). Formula: Market Price ÷ EPS. Unlike EV multiples, P/E is an equity-level multiple — it is affected by capital structure and therefore appropriate only when comparing companies with similar debt levels.
- Best for: Listed company benchmarking for mature businesses; financial services (banks, NBFCs, insurance) where EBITDA is not a meaningful concept because interest income and expense are core to the business model.
- Limitation: Sensitive to one-time items in PAT (exceptional gains or losses, deferred tax movements). Always compute P/E on normalised PAT — PAT adjusted to exclude non-recurring items.
EV / EBIT — For High-Depreciation Industries
Infrastructure
Capital-Intensive Sectors
- What it measures: Enterprise Value relative to Earnings Before Interest and Tax (after depreciation). Formula: EV ÷ EBIT.
- Best for: Industries where depreciation is a genuine economic cost that should not be added back — infrastructure, airlines, asset-heavy manufacturing. When depreciation is large and economically meaningful (as opposed to an accounting artefact), EV/EBIT is more representative than EV/EBITDA.
- Limitation: Sensitive to differences in depreciation methods and asset ages between peer companies. A company with fully depreciated assets will show a lower EBIT charge than a recently-investing peer — making like-for-like comparison unreliable without normalisation of the depreciation charge across the peer set.
P / BV (Price to Book Value) — For Financial Institutions
Banks & NBFCs
Asset-Heavy Businesses
- What it measures: Market price relative to book value of equity (net assets per share). Formula: Market Price ÷ Book Value per share.
- Best for: Banks, NBFCs, insurance companies — businesses where the balance sheet (loan book, investment portfolio) is the primary value driver, and P&L multiples do not capture balance sheet quality differences between peers.
- Limitation: Book value is heavily influenced by accounting policies, provisioning norms, and asset quality — two banks with identical P/BV multiples may have materially different underlying asset quality. P/BV must always be read alongside Return on Equity (RoE) and Non-Performing Asset (NPA) ratios to assess whether the book value being referenced is clean and comparable.
Typical EV/EBITDA Ranges Across Indian Sectors (FY2026)
FMCG / Branded Consumer 25x – 50x
IT / Technology Services 18x – 28x
Pharmaceuticals 14x – 22x
Healthcare Technology 16x – 26x
Specialty Chemicals 12x – 20x
Manufacturing (General) 8x – 16x
Infrastructure / EPC 7x – 13x
Logistics / Warehousing 9x – 15x
Note: Ranges reflect typical NSE/BSE-listed peer trading multiples as of early 2026. Actual multiples depend on company-specific growth, margins, and market conditions. Use as directional guidance only — always derive multiples from a contemporaneous peer set for any Valuation assignment.
How Is Enterprise Value Calculated from Multiples?
Once the comparable set is assembled and the appropriate multiples are extracted, the computation of Enterprise Value is straightforward — but precision in the inputs is non-negotiable. The valuer extracts the EV/EBITDA, EV/Revenue, and P/E multiples from the comparable companies' market data, computes the median (or a weighted average in specific cases), and applies it to the corresponding financial metric of the subject company.
CCM Core Formulas — Enterprise Value Computation
| Multiple Approach | Formula | Key Metric Definition |
|---|---|---|
| EV / EBITDA Approach | EV = Subject EBITDA × Median Peer EV/EBITDA | EBITDA = Earnings Before Interest, Tax, Depreciation & Amortisation |
| EV / Revenue Approach | EV = Subject Revenue × Median Peer EV/Revenue | Revenue = Total Operating Revenue (net of GST) |
| P / E Approach | Market Cap = Subject Normalised PAT × Median Peer P/E | PAT = Profit After Tax, normalised for one-time items |
| Median Multiple | Middle value of the ranked comparable set | Use median, not mean — robust against outliers |
| Equity Value (Final) | Equity Value = EV − Net Debt − Debt-like Items + Cash | Per Share = Equity Value ÷ Diluted Shares Outstanding |
LTM vs NTM: Choose Last Twelve Months (LTM) for stable businesses; Next Twelve Months (NTM) for high-growth companies. Apply the same period to both comparable companies and the subject — mixing periods creates a systematic valuation distortion.
The critical choice between LTM (Last Twelve Months) and NTM (Next Twelve Months) financials must be made consistently across both the comparables and the subject company. LTM multiples use audited historical figures and are appropriate when historical performance is a reliable indicator of current earning capacity. NTM multiples use analyst forecasts for the peer companies and estimated projections for the subject — appropriate when the business is in a growth transition where the last twelve months significantly understates current scale. For most Indian unlisted Company Valuation assignments, LTM is the default, given the absence of external analyst coverage for the subject.
How Do You Adjust Multiples for Better Accuracy?
Raw median multiples from the comparable set cannot be applied mechanically. The comparable companies are publicly listed — they carry a liquidity premium relative to unlisted companies, they may differ from the subject on key value drivers, and their financial metrics may include one-time items that distort the multiple. Four categories of adjustment are required before the multiple is applied.
| Adjustment Type | Why It Is Needed | Direction | Typical Quantum |
|---|---|---|---|
| Normalisation of financials | Remove one-time items (exceptional income/loss, COVID-era distortions) from both peer and subject EBITDA/PAT | Varies | Case-specific |
| Size adjustment | Smaller companies have less market liquidity and higher idiosyncratic risk than larger listed peers | Discount to median | 5% – 20% |
| Growth differential | If subject company grows materially faster than peers, it may warrant a premium to the median multiple | Premium or Discount | 5% – 25% |
| Margin differential | Higher EBITDA margin peers command higher multiples — subject company at lower margin should apply a discount | Discount to median | 5% – 20% |
SNIPPET — LTM vs. NTM: Which to Use?
- LTM (Last Twelve Months): Use audited financials for the most recent 12-month period. Appropriate for stable, mature businesses where history is a reliable guide to current earnings power. More defensible in regulatory Valuation — based on audited numbers.
- NTM (Next Twelve Months): Use estimated forward financials for the coming 12-month period. Appropriate for fast-growing companies where LTM materially understates current scale. Requires management projections for the subject company and analyst forecasts for peers. Less common in IBBI-registered valuer reports due to subjectivity of forward estimates for unlisted companies.
- Rule: Whichever period is chosen, it must be applied consistently to both the comparable companies and the subject company. Mixing LTM peers with NTM subject metrics is a methodological error that produces a distorted multiple and an unreliable Valuation output.
🎁 Get the Free CCM Valuation Excel Template
Download our comparable company analysis template — used by our team on real client Valuations. Free, no macros, ready to use.
Step-by-Step CCM Worked Example: ABC India
The following worked example applies the CCM method to a realistic unlisted Indian company. Every number, computation, and adjustment is shown explicitly so that the reader can follow the full methodology from first input to final per-share Valuation. This is the same rigour applied by our team in Valuation reports.
📋 Subject Company Profile
ILLUSTRATIVE EXAMPLE
| Parameter | Details |
|---|---|
| Company Name | ABC India Private Limited |
| Registered Office | Pune, Maharashtra |
| Business Description | B2B SaaS-based hospital management system (HMS) and clinical decision support software for mid-size private hospitals and diagnostic chains across India |
| Revenue (FY2026 LTM) | Rs. 85.0 crore |
| EBITDA (FY2026 LTM) | Rs. 18.7 crore (Margin: 22.0%) |
| EBIT (FY2026 LTM) | Rs. 14.2 crore (after Rs. 4.5 crore depreciation) |
| Normalised PAT | Rs. 10.5 crore (after removing Rs. 1.2 crore one-time government grant) |
| Revenue Growth (3yr CAGR) | 27% |
| Gross Debt (as at 31 March 2026) | Rs. 15.0 crore (term loan; fully secured) |
| Cash & Equivalents | Rs. 3.0 crore |
| Net Debt | Rs. 12.0 crore |
| Total Shares Outstanding (fully diluted) | 1,00,00,000 (1 crore shares) |
| Valuation Purpose | Series B funding round — new share issuance to a strategic investor |
Step 1 — Assemble the Comparable Company Set
Applying the six-screen selection process described above to NSE/BSE-listed healthcare technology and hospital management software companies, the following five companies are selected as the final comparable set. Two candidates — a large conglomerate with a healthcare division and a diagnostics chain operator — were excluded as non-comparable business models.
📊 Step 1 — Comparable Company Set (NSE/BSE Listed Peers)
ILLUSTRATIVE DATA
| Company | Revenue (Rs. Cr) | EBITDA (Rs. Cr) | EBITDA Margin | Revenue Growth (3yr CAGR) | Market Cap (Rs. Cr) | Net Debt (Rs. Cr) | EV (Rs. Cr) |
|---|---|---|---|---|---|---|---|
| Healtheon Technologies Ltd | 112 | 26.9 | 24% | 21% | 500 | 15 | 515 |
| MedLink Systems Ltd | 68 | 13.6 | 20% | 19% | 218 | 7 | 225 |
| CureLink Software Ltd | 145 | 40.6 | 28% | 32% | 870 | 10 | 880 |
| Apex HealthTech Ltd | 55 | 8.8 | 16% | 14% | 123 | 5 | 128 |
| DiagnoFirst India Ltd | 92 | 20.2 | 22% | 24% | 385 | 3 | 388 |
Step 2 — Extract and Rank the Trading Multiples
With the comparable companies identified and their Enterprise Values computed (Market Capitalisation + Net Debt), the three primary multiples are calculated for each peer. The multiples are ranked in ascending order to identify the median — the middle value, which is used in preference to the mean to avoid distortion by outliers.
📊 Step 2 — Multiple Extraction and Median Computation
ILLUSTRATIVE DATA
| Company | EV / EBITDA | EV / Revenue | P / E (Norm. PAT) |
|---|---|---|---|
| Apex HealthTech Ltd (lowest) | 14.5x | 2.3x | 20.0x |
| MedLink Systems Ltd | 16.5x | 3.3x | 24.0x |
| Healtheon Technologies Ltd ← MEDIAN | 19.1x | 4.6x | 28.5x |
| DiagnoFirst India Ltd | 19.2x | 5.2x | 29.0x |
| CureLink Software Ltd (highest) | 21.7x | 6.1x | 35.0x |
| 📍 MEDIAN (3rd of 5) | 19.1x | 4.6x | 28.5x |
| Mean (for reference only) | 18.2x | 4.3x | 27.3x |
EV/Revenue median is Healtheon at 4.6x — DiagnoFirst at 5.2x and CureLink at 6.1x fall above the median. All values are LTM. Mean shown for reference only; median is used in the valuation to avoid distortion by outliers.
Step 3 — Apply Median Multiples to Subject Company Financials
The median multiples are now applied to ABC India's corresponding financial metrics. Three parallel Valuation computations are run — one for each multiple — and the results are reviewed for internal consistency before a final Enterprise Value is selected.
🔢 Step 3 — Enterprise Value Computation
ILLUSTRATIVE DATA
| Method | Subject Metric | Median Multiple | Implied EV (Rs. Crore) | Weight Assigned |
|---|---|---|---|---|
| EV / EBITDA | Rs. 18.7 crore | 19.1x | Rs. 357.2 crore | 50% |
| EV / Revenue | Rs. 85.0 crore | 4.6x | Rs. 391.0 crore | 30% |
| P / E (equity, not EV) | Rs. 10.5 crore PAT | 28.5x | Rs. 299.3 crore (Mkt Cap) | 20% |
|
Weighted Average Enterprise Value (EV/EBITDA × 50% + EV/Rev × 30% + P/E EV-equiv × 20%) P/E output converted to EV: Rs. 299.3 + Rs. 12.0 net debt = Rs. 311.3 crore EV equivalent | Weighted: (357.2 × 50%) + (391.0 × 30%) + (311.3 × 20%) = Rs. 358.2 crore | Rs. 358.2 crore | 100% | ||
🔍 Not Sure What Your Company Is Worth?
Most founders and CFOs are surprised by the gap between what they think their company is worth and what the market actually supports. Our team will run a quick CCM analysis for your sector — and tell you exactly where your business stands relative to listed peers.
How Do You Bridge from EV to Per-Share Value?
Enterprise Value represents the total value of the business to all capital providers — equity shareholders and debt holders combined. To arrive at the Equity Value — what the equity shareholders own — net debt and all other debt-like obligations must be subtracted, and any cash-like items added. This EV-to-Equity bridge is the step where most CCM Valuation errors are made, because the balance sheet contains items that are economically debt-like (and must be deducted) or cash-like (and must be added) even when they are not labelled as "debt" or "cash" on the face of the balance sheet.
🔗 Step 4 — EV to Equity Value Bridge: ABC India
ILLUSTRATIVE DATA
| Particulars | Amount (Rs. Crore) |
|---|---|
| Enterprise Value (Weighted CCM Output) | Rs. 358.2 crore |
| Less: Term Loan (Gross Debt) | (Rs. 15.0 crore) |
| Less: Finance Lease Liabilities (Ind AS 116) | (Rs. 1.2 crore) |
| Add: Cash & Cash Equivalents | + Rs. 3.0 crore |
| Add: Short-Term Investments (liquid) | + Rs. 0.8 crore |
| Less: Contingent Liability (tax dispute; 60% probability) | (Rs. 1.5 crore) |
| Less: Unfunded Gratuity Liability | (Rs. 0.6 crore) |
| Equity Value (Pre-Discount) — 100% Basis | Rs. 343.7 crore |
Note: Minority interest is nil — ABC India has no subsidiaries. Contingent liability probability-weighted at 60% per management representation. All items verified against audited balance sheet as at 31 March 2026.
What Discounts Apply to Unlisted Company CCM?
The Equity Value of Rs. 343.7 crore derived above is based on listed peer trading multiples — multiples that reflect the price at which investors can buy and sell shares freely and instantaneously on the NSE or BSE. ABC India Private Limited is an unlisted company. An investor who buys shares in ABC India cannot exit through a public market — they must find a buyer through a private negotiation, which takes time, involves transaction costs, and carries uncertainty of outcome. This illiquidity commands a discount relative to listed-market-derived value.
Two discounts are potentially applicable, and their sequencing matters: the Discount for Lack of Marketability (DLOM) is applied first, to the 100% Equity Value; the Discount for Lack of Control (DLOC) is then applied to the post-DLOM value, but only when the interest being valued is a minority stake (less than 50%).
Discount for Lack of Marketability (DLOM) — Illiquidity Discount
Applied to All Unlisted Companies
Typical Range: 15% – 35%
DLOM compensates for the absence of a liquid exit market for the shares. The discount is derived from empirical studies — restricted stock studies (difference between restricted and freely tradeable stock prices for the same company) and pre-IPO studies (difference between private placement prices and eventual IPO prices). Our team derives DLOM using a structured framework considering: (1) time to likely exit (IPO, strategic sale); (2) company size — smaller companies attract higher discounts; (3) financial health — profitable, growing companies attract lower discounts; (4) existing shareholder agreements — put/call options narrow the DLOM. For ABC India, a 20% DLOM is applied — at the lower end of the range, reflecting the company's strong growth, profitability, and strategic attractiveness for an exit within 3–4 years.
Discount for Lack of Control (DLOC) — Minority Discount
Applied Only for Minority Stake Valuation
Typical Range: 10% – 25%
DLOC applies when the interest being valued represents less than a 50% (non-controlling) stake. A minority shareholder cannot independently direct management decisions, set dividend policy, approve related-party transactions, or initiate a sale — all of which have economic value. The DLOC compensates for this absence of control. In the ABC India example, the Series B funding is for a 20% stake — a minority position. A DLOC of 15% is applied. Note: if the subject company is being valued on a 100% controlling interest basis (as for an M&A acquisition), DLOC is not applied.
Is DLOC Applicable When the Subject Company Is Listed?
A question that frequently arises in practice — particularly in SEBI fairness opinions, open offer pricing, and swap ratio Valuations — is whether DLOC can or should be applied when the CCM method is used for a listed subject company. The answer requires understanding the level of value that CCM multiples inherently reflect, and whether a further minority discount would result in double-counting.
■■ Core Principle — Level of Value: CCM multiples are derived from market-traded share prices of listed peers. Those prices represent what a small, non-controlling investor pays on the stock exchange — i.e., they already reflect a minority, freely tradeable (marketable) interest. Applying DLOC on top of multiples that are already priced at the minority level is a double discount, which is not professionally acceptable and will not withstand scrutiny from SEBI, NCLT, or a counterparty's advisor.
The correct analysis depends on the type of multiple used and the interest being valued:
| Scenario | Multiple Type | Implied Level of Value | DLOC Acceptable? |
|---|---|---|---|
| CCM using equity multiples (P/E, P/BV) | Equity-level | Minority, marketable — minority discount already embedded in traded price | ❌ No — double discount |
| CCM using EV multiples, valuing a controlling interest | Enterprise-level | Control-level enterprise value (EV approximates acquisition price | ❌ Not applicable |
| CCM using EV multiples, valuing a minority interest in an unlisted company | Enterprise-level | EV → equity bridge arrives at controlling-interest equity; DLOC is a legitimate further step | ✔ Yes — standard practice |
| CCM used for a listed subject company (any multiple type) | Any | Observable market price is already the minority-marketable anchor for that company | ❌ Generally not acceptable |
When the subject company is listed, applying CCM and then additionally deducting DLOC would produce a value below the company's own observable market price — a position that is difficult to justify unless there are specific, documented reasons such as severe thin-trading or a structural illiquidity in the subject's own shares (which is a separate DLOM-type argument, not a DLOC argument). In SEBI-regulated transactions — open offers, delisting, scheme of arrangement — the market price serves as a floor for minority protection; a DLOC deduction below this floor is contrary to the regulatory intent of those provisions.
Under ICAI Valuation Standards (VS 103), the valuer must identify the standard of value and the level of value (controlling vs. non-controlling; marketable vs. non-marketable) at the outset, and ensure that adjustments are internally consistent and not double-counted. IVS 200 is explicit that if multiples are drawn from minority market transactions, the resulting indication is already at the non-controlling, marketable level — a control premium would need to be added (not a discount deducted) if a controlling interest value is required. The DLOC question in a listed-company CCM context is therefore not a close call — it is a level-of-value consistency issue that any well-documented Valuation report must address.
💰 Step 5 — Applying Discounts: Final Per-Share Value
ILLUSTRATIVE DATA
| Valuation Step | Description | Value |
|---|---|---|
| Equity Value (Pre-Discount) | 100% basis derived from CCM valuation before applying any discounts | Rs. 343.7 crore |
| Less: DLOM — 20% | Illiquidity discount for unlisted company status | (Rs. 68.7 crore) |
| Equity Value Post-DLOM | Marketable minority basis after applying DLOM | Rs. 274.9 crore |
| Less: DLOC — 15% | Minority discount applied for 20% stake valuation | (Rs. 41.2 crore) |
| Equity Value — Minority, Non-Marketable | Final equity value after all applicable discounts | Rs. 233.7 crore |
| Total Shares Outstanding | Fully diluted share count | 1,00,00,000 shares |
| 💎 Fair Value Per Share | Minority, non-marketable basis per share value | Rs. 234 per share |
Sensitivity Analysis — Key Variable Impact on Per-Share Value
Our valuation analysis includes a sensitivity table showing how the per-share value changes under different assumptions for the two key variables — the EV/EBITDA multiple applied, and the DLOM percentage. This allows the investor and the board to understand the impact of assumptions on the final value.
| EV/EBITDA Applied ↓ | DLOM → | 15% | 20% (Base) | 25% | 30% |
|---|---|---|---|---|
| 16x (Low Peer Multiple) | Rs. 206 | Rs. 194 | Rs. 181 | Rs. 169 |
| 18x | Rs. 233 | Rs. 219 | Rs. 205 | Rs. 192 |
| 19.1x (Base — Median) | Rs. 248 | Rs. 234 ★ | Rs. 218 | Rs. 204 |
| 21x | Rs. 273 | Rs. 257 | Rs. 241 | Rs. 225 |
| 23x (High Peer Multiple) | Rs. 300 | Rs. 283 | Rs. 265 | Rs. 247 |
Green = High value zone | Amber = Mid value zone | Red = Low value zone. DLOC of 15% applied consistently across all scenarios. All values are on a minority, non-marketable basis. For illustration only — not a valuation opinion.
How Does CCM Compare to DCF Valuation?
No professional Valuation is built on a single method. IBBI-registered valuers are required to apply multiple approaches and cross-check the results. Understanding how CCM and DCF interact — and when each is more reliable — is essential for anyone interpreting a Valuation report or commissioning a Valuation.
| Dimension | CCM Method | DCF Method |
|---|---|---|
| Foundation | Current market pricing of comparable businesses | Intrinsic value based on future cash flow projections |
| Key Input | Comparable company multiples (EV/EBITDA, P/E) | WACC, projected FCF, terminal growth rate |
| Reflects Market Sentiment | Yes — automatically incorporates current market conditions | No — independent of current market pricing |
| Suitable for Loss-Making Companies | Partially — use EV/Revenue or EV/GMV | Yes — if terminal profitability can be modelled |
| Speed of Execution | Fast once peer set is assembled | Slow — requires full 5–7 year financial model |
| Manipulation Risk | Lower — anchored to market data | Higher — terminal value assumption drives 60–80% of output |
| Best for Negotiation | Yes — market-anchored number is defensible to counterparty | Less so — counterparty challenges every assumption |
SNIPPET — How Our Team Uses CCM and DCF Together
When CCM and DCF outputs diverge significantly (more than 20–25%), our team investigates the source of divergence before concluding on the final value. Common sources of divergence: (1) the DCF uses an aggressive growth assumption not supported by historical performance — projections are normalised; (2) the peer multiple is elevated by exceptional market conditions (sector re-rating, M&A activity) — a market adjustment is applied; (3) the subject company has a structural advantage (IP, regulatory licence) not captured in peer multiples — a premium is applied. The final Valuation conclusion is a single, well-supported point value — supported by this sensitivity table to show how it would shift under alternate assumptions.
What Are the Most Common CCM Errors to Avoid?
CCM appears deceptively straightforward. The frequency of errors in CCM Valuation — even by finance professionals — is high precisely because the method seems simple while demanding rigorous professional judgement at every step. The following are the errors most commonly encountered by our team when reviewing third-party Valuation reports.
Error 1 — Using Non-Comparable Peers
Critical Error
Including large diversified conglomerates, companies in tangentially related sectors, or companies with fundamentally different margin profiles in the comparable set. This inflates or deflates the median multiple and produces a Valuation detached from market reality. The fix: apply all five screening criteria rigorously and document exclusion rationale.
Error 2 — Using Mean Instead of Median
Common Error
Averaging the multiples of five comparables when one or two outliers (a company with an exceptional growth premium, or a distressed peer trading below intrinsic value) pull the mean away from the central tendency. The median is statistically robust to outliers. Always use the median in a set of five to eight comparables.
Error 3 — Mixing LTM and NTM Periods
Critical Error
Extracting peer multiples on a forward (NTM) basis while applying them to the subject company's historical (LTM) EBITDA — or vice versa. This creates a systematic distortion. If peers trade at 18x NTM EBITDA (reflecting future earnings), that multiple applied to LTM EBITDA (historical, lower earnings) produces an overvaluation. Period consistency is non-negotiable.
Error 4 — Omitting Debt-Like Items from the Bridge
Critical Error
The EV-to-Equity bridge frequently misses: lease liabilities under Ind AS 116 (operating leases are now on-balance-sheet debt); deferred payment consideration on acquisitions; contingent liabilities with reasonable probability of crystallisation; unfunded gratuity and pension obligations; and loans given to subsidiaries or related parties that may not be recoverable (effectively a debt-like cash drain). Missing any of these overstates Equity Value.
Error 5 — Applying No or Incorrect Discounts
Common Error
Applying listed peer multiples to an unlisted company without any DLOM — or applying a DLOM without documented rationale — are both errors. The former systematically overvalues the unlisted company by the listed liquidity premium. The latter produces an indefensible Valuation that cannot survive regulatory scrutiny. The DLOM quantum must be supported by reference to empirical studies or recognised quantification methods (Mandelbaum factors, Finnerty average-strike put option model).
📊 Get a CCM Valuation Report — Delivered in 5 Business Days
Raise a funding round, price an ESOP grant, comply with FEMA, or prepare for an M&A deal — our team delivers a fully documented, defensible CCM Valuation report with peer-set analysis, multiple computation, EV bridge, and per-share value. Trusted by 200+ companies across India.
Closing Summary: Applying CCM with Precision
The Comparable Company Multiple method is the most powerful and most widely misapplied Valuation tool in Indian practice. When executed correctly — with a rigorously screened peer set, properly computed and normalised multiples, consistently applied financial periods, a complete EV-to-Equity bridge, and defensible discount quantification — CCM produces a Valuation that is empirically grounded, transparent, and professionally accountable. The worked example of ABC India Private Limited in this guide demonstrates the full methodology from peer selection through to a single, well-supported per-share value of Rs. 234, with a sensitivity matrix that clearly shows how that value moves under different assumptions — giving both the client and the reader full transparency over the analysis. Elite Valuation's team brings this standard of rigour to every CCM Valuation mandate — across sectors, transaction types, and regulatory contexts — pan-India.
Download Our Free CCM Valuation Excel Template
Searching for a free CCM valuation template, a comparable company analysis Excel template India, or a market multiples valuation model you can use right away? We've built one — and it's free to download.
Our CCM Valuation Excel Template is the same structured model our team uses for client engagements. It includes a peer data input sheet, automatic median computation for EV/EBITDA, EV/Revenue, and P/E, a pre-built EV-to-Equity bridge, DLOM and DLOC discount inputs, and a sensitivity table that auto-populates when you change assumptions. No macros, no passwords — just a clean, ready-to-use comparable company analysis template for Indian Valuations.
📥 FREE DOWNLOAD — What's Inside the CCM Template
Tab 1 — Peer Data: Enter revenue, EBITDA, PAT, market cap, and net debt for up to 8 comparable companies. EV and all three multiples compute automatically.
Tab 2 — Median & Multiple Selection: Ranked multiple table with auto-highlighted median, mean for reference, and input cell for the multiple you choose to apply.
Tab 3 — EV-to-Equity Bridge: Pre-built bridge with cells for gross debt, lease liabilities (Ind AS 116), cash, contingent liabilities, gratuity, and diluted shares.
Tab 4 — DLOM/DLOC Discounts: Input DLOM % and DLOC % — post-discount Equity Value and per-share value update instantly.
Tab 5 — Sensitivity Table: 5×4 sensitivity matrix (EV/EBITDA multiple vs DLOM %) — colour-coded automatically in green / amber / red.
🎁 Get the Free CCM Valuation Excel Template
Download our comparable company analysis template — used by our team on real client Valuations. Free, no macros, ready to use.
Frequently Asked Questions — CCM Valuation
CA Sagar Shah, Founder
Mr Sagar Shah is the Founder of Elite Valuation and leads the firm’s Valuation and Advisory practice. With over 15+ years of professional experience.
